TWP 102
Alternative Names: TWP-102Latest Information Update: 14 Mar 2022
At a glance
- Originator Shandong TheraWisdom Biopharm
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 08 Mar 2022 Phase-I clinical trials in Cancer (Late-stage disease, Second-line therapy or greater) in China (IV) in March 2022 (NCT05024305)
- 27 Aug 2021 Shandong TheraWisdom Biopharma plans a phase I trial for Cancer (Late-stage disease) in China (IV, Infusion), in November 2021 (NCT05024305)
- 27 Aug 2021 Preclinical trials in Cancer in China (IV), prior to August 2021